Ultralarge Von Willebrand Factor-Induced Platelet Clumping and Activation of the Alternative Complement Pathway in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndromes

Hematology/Oncology Clinics of North America

Volumn 29, Issue 3, 2015, Pages 509-524

  Turner, Nancy ^a   Sartain, Sarah ^a,b   Moake, Joel ^a  

^a Rice University   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alternative complement pathway; Factor H; Thrombotic microangiopathies; VWF

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CD59 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE COFACTOR PROTEIN; THROMBOMODULIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; ADAMTS13 GENE; ATYPICAL HEMOLYTIC SYNDROME; C3 GENE; CD46 GENE; CFB GENE; CFH GENE; CFHR1 GENE; CFHR3 GENE; CFI GENE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE ASSOCIATION; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENTEROHEMORRHAGIC ESCHERICHIA COLI ASSOCIATED HEMOLYTIC SYNDROME; GENE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC PREDISPOSITION; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTRAVASCULAR HEMOLYSIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN PROTEIN INTERACTION; REVIEW; THBD GENE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; BIOLOGICAL MODEL; ENDOTHELIUM CELL; IMMUNOLOGY; METABOLISM; THROMBOCYTE ACTIVATION;

COMPLEMENT C3; COMPLEMENT PATHWAY, ALTERNATIVE; ENDOTHELIAL CELLS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MODELS, IMMUNOLOGICAL; PLATELET ACTIVATION; PLATELET AGGREGATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 84930043360     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.01.008     Document Type: Review

References (68)

1. Moake J.L. Thrombotic microangiopathies. NEngl J Med 2002, 347(8):589-600.
2. Turner N.A., Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One 2013, 8(3):e59372.
3. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. NEngl J Med 1998, 339(22):1578-1584.
4. Furlan M., Robles R., Solenthaler M., et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997, 89(9):3097-3103.
5. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. NEngl J Med 1998, 339(22):1585-1594.
6. Garg A.X., Suri R.S., Barrowman N., et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003, 290:1360-1370.
7. Keir L.S., Marks S.D., Kim J.J. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 2012, 6:195-208.
8. Nolasco L.H., Turner N.A., Bernardo A., et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005, 106(13):4199-4209.
9. Delmas Y., Vendrely B., Clouzeau B., et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014, 29(3):565-572.
10. Kielstein J.T., Beutel G., Fleig S., et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012, 27(10):3807-3815.
11. Cleary T.G. Cytotoxin producing Escherichia coli and the hemolytic uremic syndrome. Pediatr Clin North Am 1988, 35:485-501.
12. Matussek A., Lauber J., Bergau A., et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 2003, 102(4):1323-1332.
13. He X., Quinones B., McMahon S., et al. Asingle-step purification and molecular characterization of functional Shiga toxin 2 variants from pathogenic Escherichia coli. Toxins (Basel) 2012, 4(7):487-504.
14. Odumosu O., Nicholas D., Yano H., et al. AB toxins: a paradigm switch from deadly to desirable. Toxins (Basel) 2010, 2:1612-1645.
15. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365(9464):1073-1086.
16. Trachtman H., Austin C., Lewinski M., et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012, 8(11):658-669.
17. Loirat C., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011, 6(1):60.
18. Maga T.K., Nishimura C.J., Weaver A.E., et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010, 31(6):E1445-E1460.
19. Zipfel P.F., Edey M., Heinen S., et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007, 3(3):e41.
20. Frémeaux-Bacchi V., Miller E.C., Liszewski M.K., et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112(13):4948-4952.
21. Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007, 104(1):240-245.
22. Roumenina L.T., Loirat C., Dragon-Durey M.A., et al. Alternative complement pathway assessment in patients with atypical HUS. JImmunol Methods 2011, 365(1-2):8-26.
23. Law S.K., Levine R.P. Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci USA 1977, 74(7):2701-2705.
24. Pangburn M.K., Ferreira V.P., Cortes C. Discrimination between host and pathogens by the complement system. Vaccine 2008, 26(Suppl 8):I15-I21.
25. Law S.K., Dodds A.W. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 1997, 6(2):263-274.
26. Schreiber R.D., Pangburn M.K., Lesavre P.H., et al. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci USA 1978, 75(8):3948-3952.
27. Fearon D.T., Austen K.F., Ruddy S. Formation of a hemolytically active cellular intermediate by the interaction between properdin, factors B and D and the activated third component of complement. JExp Med 1973, 138(6):1305-1313.
28. Pillemer L., Blum L., Lepow I.H., et al. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 1954, 120(3112):279-285.
29. Weiler J.M., Daha M.R., Austen K.F., et al. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA 1976, 73(9):3268-3272.
30. Kinoshita T., Takata Y., Kozono H., et al. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. JImmunol 1988, 141(11):3895.
31. Rawal N., Pangburn M. Formation of high-affinity C5 convertases of the alternative pathway of complement. JImmunol 2001, 166(4):2635-2642.
32. Bernardo A., Ball C., Nolasco L., et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004, 104(1):100-106.
33. Huang J., Motto D.G., Bundle D.R., et al. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood 2010, 116(18):3653-3659.
34. Klegeris A., Bissonnette C.J., Dorovini-Zis K., et al. Expression of complement messenger RNAs by human endothelial cells. Brain Res 2000, 871(1):1-6.
35. Langeggen H., Berge K.E., Macor P., et al. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells invitro. APMIS 2001, 109(1):73-78.
36. Langeggen H., Pausa M., Johnson E., et al. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000, 121(1):69-76.
37. Wurzner R., Joysey V.C., Lachmann P.J. Complement component C7. Assessment of invivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. JImmunol 1994, 152(9):4624-4629.
38. Cines D.B., Pollak E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91(10):3527-3561.
39. Cataland S.R., Holers V.M., Geyer S., et al. Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 2014, 123:3733-3738.
40. Thurman J.M., Marians R., Emlen W., et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009, 4(12):1920-1924.
41. Hattori R., Hamilton K.K., McEver R.P., et al. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. JBiol Chem 1989, 264(15):9053-9060.
42. Reti M., Farkas P., Csuka D., et al. Complement activation in thrombotic thrombocytopenic purpura. JThromb Haemost 2012, 10(5):791-798.
43. Ruiz-Torres M.P., Casiraghi F., Galbusera M., et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005, 93(3):443-452.
44. Chapin J., Weksler B., Magro C., et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012, 157(6):772-774.
45. Tsai E., Chapin J., Laurence J.C., et al. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 2013, 162(4):558-559.
46. Courteciosse V., Habib R., Monnier C. Nonlethal hemolytic and uremic syndromes in children: an electron-microscope study of renal biopsies from six cases. Exp Mol Pathol 1967, 7:327-347.
47. Katz J., Krawitz S., Sacks P.V., et al. Platelet, erythrocyte, and fibrinogen kinetics in the hemolytic-uremic syndrome of infancy. JPediatr 1973, 83(5):739-748.
48. Siegler R.L., Pysher T.J., Tesh V.L., et al. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. JAm Soc Nephrol 2001, 12:1458-1467.
49. Pysher T.J., Siegler R.L., Tesh V.L., et al. von Willebrand factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome. Pediatr Dev Pathol 2002, 5(5):472-479.
50. Studt J.D., Bohm M., Budde U., et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. JThromb Haemost 2003, 1(9):1882-1887.
51. Tsai H.M., Chandler W.L., Sarode R., et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli 0157: H7-associated hemolytic uremic syndrome. Pediatr Res 2001, 49:653-659.
52. Lo N.C., Turner N.A., Cruz M.A., et al. Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor. JBiol Chem 2013, 288(46):33118-33123.
53. Morigi M., Galbusera M., Gastoldi S., et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. JImmunol 2011, 187(1):172-180.
54. Orth D., Khan A.B., Naim A., et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. JImmunol 2009, 182(10):6394-6400.
55. Ehrlenbach S., Rosales A., Posch W., et al. Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 2013, 81(8):2678-2685.
56. Nolasco L., Nolasco J., Feng S., et al. Human complement factor H is a reductase for large soluble von Willebrand factor multimers-brief report. Arterioscler Thromb Vasc Biol 2013, 33(11):2524-2528.
57. Kim Y., Miller K., Michael A.F. Breakdown products of C3 and factor B in hemolytic-uremic syndrome. JLab Clin Med 1977, 89(4):845-850.
58. Monnens L., Molenaar J., Lambert P.H., et al. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 1980, 13(4):168-171.
59. Robson W.L., Leung A.K., Fick G.H., et al. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 1992, 62(3):296-299.
60. Lapeyraque A.L., Malina M., Fremeaux-Bacchi V., et al. Eculizumab in severe Shiga-toxin-associated HUS. NEngl J Med 2011, 364(26):2561-2563.
61. Feng S., Eyler S.J., Zhang Y., et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood 2013, 122:1487-1493.
62. Feng S., Kroll M.H., Nolasco L., et al. Complement activation in thrombotic microangiopathies. Br J Haematol 2013, 160(3):404-406.
63. Sartz L., Olin A.I., Kristoffersson A.C., et al. Anovel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. JImmunol 2012, 188(4):2030-2037.
64. Delvaeye M., Noris M., De Vriese A., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. NEngl J Med 2009, 361(4):345-357.
65. Bull B.S., Kuhn I.N. The production of schistocytes by fibrin strands (a scanning electron microscope study). Blood 1970, 35(1):104-111.
66. Savage W.J., Barber J.P., Mukhina G.L., et al. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol 2009, 37(1):42-51.
67. Rollins S.A., Sims P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. JImmunol 1990, 144(9):3478-3483.
68. Canalejo K., Riera Cervantes N., Felippo M., et al. Paroxysmal nocturnal haemoglobinuria. Experience over a 10 years period. Int J Lab Hematol 2014, 36(2):213-221.